<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661736</url>
  </required_header>
  <id_info>
    <org_study_id>17.09.CLI</org_study_id>
    <nct_id>NCT03661736</nct_id>
  </id_info>
  <brief_title>Growth of Infants With Cow's Milk Allergy Fed an Amino Acid-based Formula Containing Two Human Milk Oligosaccharides</brief_title>
  <acronym>PLATYPUS</acronym>
  <official_title>Growth of Infants With Cow's Milk Allergy Fed an Amino Acid-based Formula Containing Two Human Milk Oligosaccharides: Comparison With World Health Organization (WHO) Growth Standards in an Observational, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to provide longitudinal growth data in infants with&#xD;
      moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human&#xD;
      milk oligosaccharides.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The weight-for-age z-score (WAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>Comparison of baseline WAZ vs WAZ at 4 months</time_frame>
    <description>Weight gain will be measured in kg and converted to WAZ scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length-for-age Z-scores (LAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>1, 2, 3, 4 months from baseline and at 12 months of age</time_frame>
    <description>Body length will be measured in cm and converted to LAZ scores</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Head circumference (HCAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>1, 2, 3, 4 months from baseline and at 12 months of age</time_frame>
    <description>Head circumference will be measured in cm converted to HCAZ scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Monitoring of CMPA-related symptoms</measure>
    <time_frame>1, 2, 3 and 4 months from baseline and at 12 months of age</time_frame>
    <description>CMPA-related symptoms will be documented by the study physician on data collection forms</description>
  </other_outcome>
  <other_outcome>
    <measure>Faecal microbial composition</measure>
    <time_frame>Enrolment,1, 2, 3 and 4 months from treatment start and also at 12 months of age</time_frame>
    <description>Faecal samples will be collected before and after the study formula ingestion</description>
  </other_outcome>
  <other_outcome>
    <measure>Product compliance</measure>
    <time_frame>1, 2, 3 and 4 months from baseline and at 12 months of age</time_frame>
    <description>Daily quantity consumed (mL) will be recorded for the 3 days preceding each visit in a diary given to the parent or caregiver</description>
  </other_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Cow Milk Allergy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food for Specific Medical Purpose</intervention_name>
    <description>Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Full-term infants 1-8 months of age with symptoms suggestive of moderate-to-severe CMPA who&#xD;
        have failed a trial of extensively hydrolyzed formula (EHF) of at least 2 weeks or who&#xD;
        require amino acid formula as first line of treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Full term infant (37 weeks ≤ gestation ≤ 42 weeks)&#xD;
&#xD;
          2. 2500g ≤ birth weight ≤ 4500g&#xD;
&#xD;
          3. Having obtained written informed consent form the infant's parents or legally&#xD;
             authorized representatives (LAR).&#xD;
&#xD;
          4. Infant aged between 1 and 8 months.&#xD;
&#xD;
          5. Exclusively formula-fed at time of enrolment; or CMPA infant receiving partial&#xD;
             breastfeeding and infant's mother having independently elected before enrolment to&#xD;
             exclusively formula feed.&#xD;
&#xD;
          6. Infants with physician-diagnosed CMPA as per standard clinical practice:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with AAF &gt; 72 hours&#xD;
&#xD;
          2. Known underlying medical condition that would impair growth (as per physician's&#xD;
             assessment, e.g. unstable congenital heart disease, cystic fibrosis, metabolic&#xD;
             disorder, chronic liver disease etc.)&#xD;
&#xD;
          3. Demonstrated chronic malabsorption which is not due to CMPA.&#xD;
&#xD;
          4. Other significant pre-natal and/or serious post-natal disease other than CMPA before&#xD;
             enrolment (per investigator's medical decision).&#xD;
&#xD;
          5. Infants whose parents or caregivers who cannot give informed consent or who cannot be&#xD;
             expected to comply with study procedures.&#xD;
&#xD;
          6. Treatment with systemic corticosteroids (oral or intravenous) for &gt;72 hours within 4&#xD;
             weeks before enrolment (topical corticosteroids allowed)&#xD;
&#xD;
          7. Infants taking probiotic preparations for &gt; 72 hour within 4 weeks before enrolment&#xD;
&#xD;
          8. Currently participating or having participated in another clinical trial since birth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Sydney</city>
        <state>Westmead</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

